cjc-1295 vs sermorelin
updated
cjc-1295 (tier A) vs sermorelin (tier B): what each is, half-life and source counts side by side.
cjc-1295 · tier A
growth hormone without injecting growth hormone. tells your pituitary to make its own. paired with ipamorelin.
tier rationale
a synthetic GHRH analog engineered by ConjuChem to have a dramatically extended half-life, achieved by covalent binding to endogenous albumin via a drug affinity complex (DAC). comes in two forms: with DAC (6-8 day half-life, single weekly dose) and without DAC (short-acting, "Mod GRF 1-29," used in stacked protocols). the GHRH-receptor agonism mechanism is well-characterized, but a phase 2 HIV-lipodystrophy trial was discontinued after a patient death (attending physician concluded unrelated). A-tier based on mechanism plausibility and consistent user reports from peptide clinics, held back from S by the absence of a completed clinical program and no FDA approval.
sermorelin · tier B
Sermorelin is amidated GHRH(1-29). Its direct efficacy record is pediatric, while current adult sleep, recovery, and body-composition claims remain unproven.
tier rationale
The B grade reflects pediatric growth studies, diagnostic hormone responses, and human pharmacokinetics. Historic products were withdrawn, and controlled adult wellness outcomes have not been established.
at a glance
| cjc-1295 | sermorelin | |
|---|---|---|
| tier | A | B |
| category | gh / growth | gh / growth |
| sources | 20 | 11 |
| claims evaluated | 6 | n/a |
| half-life | ~6-8 days | 4.3 plus or minus 1.4 minutes after intravenous administration |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.